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Abstract
Background: A beneficial effect on glucose metabolism is reported with angiotensin receptor
blocker (ARB) treatment of hypertension. The effect on blood glucose level during the course of
treatment with ARBs in clinical cases is uncertain. Our objectives were to survey the changes in
glucose and HbA1c levels in patients with hypertension over a one-year period, and to study the
correlations between these values and the time after the start of ARB therapy.
Methods:  We conducted a retrospective longitudinal survey of blood glucose and HbA1c
measurements in Japanese patients aged ≥20 years with newly diagnosed hypertension but without
diabetes, who had received ARB monotherapy with candesartan cilexetil, losartan potassium,
olmesartan medoxomil, telmisartan, or valsartan during the period from December 2004 to
November 2005. Data including 2465 measurements of non-fasting blood glucose in 485 patients
and 457 measurements of HbA1c in 155 patients were obtained from electronic medical records
of Nihon University School of Medicine. Linear mixed effects models were used to analyze the
relationship between these longitudinal data of blood examinations and covariates of patient age,
sex, medication, and duration of ARB therapy.
Results: Casual blood glucose level was associated with the duration of treatment (P < 0.0001),
but not with age, sex, or medication. Blood glucose level was significantly decreased during the
periods of 0~3 months (P < 0.0001) and 3~6 months (P = 0.0081) compared with baseline, but was
not significantly different between 6~12 months and baseline. There was no association between
HbA1c level and covariates of sex, age, medication and duration of treatment.
Conclusion: Our findings provide new clinical evidence that the effects of ARBs on glucose
metabolism may change during the course of treatment, suggesting a blood glucose-lowering effect
in the short-term after the start of treatment.
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Background
Clinically, there are many cases in which abnormal glu-
cose metabolism and hypertension appear together.
Knowing the effects of blood pressure-lowering agents on
blood glucose is important for the treatment of hyperten-
sive patients with abnormalities of glucose metabolism or
diabetes. The agents most often used for hypertension
today include angiotensin receptor blockers (ARB) and
angiotensin converting enzyme (ACE) inhibitors, which
are both considered to improve glucose metabolism [1,2].
In addition, much attention has been paid to a prospec-
tive clinical trial that showed that ACE inhibitors sup-
pressed the new onset of diabetes [3]. A subsequent report
showed that ARBs also suppressed the new onset of diabe-
tes [4]. The magnitude of this effect was around 20–25%.
Recent animal experiments have suggested improvement
of insulin resistance by ARBs [5,6]. Clarification of the
mechanism of this effect is in progress.
In patients with essential hypertension, plasma insulin
and blood glucose levels rise together, indicating reduced
insulin sensitivity. Because of this, even without the onset
of diabetes, a latent rise in blood glucose level may be
seen. We thus selected the study subjects from among
those not diagnosed with diabetes at the time of ARB
administration, and who were being treated with an ARB
alone, at a hospital affiliated to Nihon University School
of Medicine, using medical record data for patients who
had been diagnosed with hypertension and had received
an ARB. We examined the changes in blood glucose and
HbA1c levels in these patients over a one-year period, and
then studied the correlations between these values and the
duration of ARB therapy.
Methods
Study Population
The data for this analysis were collected from a clinical
database that integrates information of inpatient and out-
patient medical records at a hospital affiliated to Nihon
University School of Medicine. The study population con-
sisted of 2635 Japanese men and women aged 20 years or
older who had been treated initially by ARB monotherapy
at usual doses for at least 4 weeks during the period from
December 2004 to November 2005, as shown in Figure 1.
Exclusion criteria included treatment with insulin and/or
a previous diagnosis of diabetes mellitus according to the
Committee for the Classification and Diagnosis of Diabe-
tes Mellitus of the Japan Diabetes Society, defined as fast-
ing plasma glucose level ≥126 mg/dl, casual plasma
glucose level ≥200 mg/dl, plasma glucose 2 h after 75 g
glucose load ≥200 mg/dl, or hemoglobin A1c (HbA1c)
level ≥6.5% [7]. Some patients had received other antihy-
pertensive drugs such as ACE inhibitors or calcium chan-
nel blockers during the 2 months before ARB therapy and
were excluded from our study. The remaining 1083
patients were subjected to further statistical analysis. The
ARBs used are listed in Table 1. Clinical data from the
study subjects included sex, age at starting treatment,
names of drugs, starting date of treatment, duration of
treatment, results of non-fasting blood examination
including blood glucose and HbA1c levels, which were
determined at the time of routine clinical visits, and date
of examination. The blood examination data were col-
lected under the criteria of having at least one value during
the 2 months before treatment or the duration of treat-
ment up to a maximum of one year. A total of 485 patients
from this population were eligible for the study of blood
glucose, and 155 subjects for HbA1c.
Statistical Analysis
Our main explanatory variables included sex, age at start-
ing treatment, medication, "duration" defined as the tim-
ing of measurement in days since the start of treatment,
coded as 0, 1, 2, or 3, with 0 indicating "baseline", i.e., ≤
time 0, and 1, 2, and 3 indicating ">0, ≤3 months", ">3,
≤6 months", and ">6, ≤12 months" since the start of treat-
ment, respectively. Our main response variables were
repeated measurements of blood glucose and HbA1c in
blood examination before and after treatment with anti-
hypertensive drugs. These data were inherently unbal-
anced because the number and timing of the repeated
measurements were different among individuals. There-
fore, linear mixed effects models were used to analyze the
relationship between these longitudinal data of blood
examination and all other covariates [8]. We fitted ran-
dom intercept and slope models to the data, including
age, sex and medication as fixed effect covariates, and
duration of treatment as random effect covariates. A
"compound symmetry" covariance was used to covary the
random intercept and slopes and estimate the covariance
between them. We selected the Kenward-Roger method to
compute the denominator degrees of freedom for the tests
of fixed effects. A multiple-comparison test (Dunnett-Hsu
post-hoc analysis) was used to compare the differences in
means between "baseline" as a reference and other times.
A result was considered statistically significant if the P
value was less than 0.05. All statistical analysis was per-
formed with SAS 9.1.3 (SAS Institute Inc., Cary, NC) sta-
tistical software.
Table 1: Angiotensin II receptor blockers
Generic name Drug name (Trade name)
candesartan cilexetil Blopress
losartan potassium Nu-Lotan
olmesartan medoxomil Olmetec
telmisartan Micardis
valsartan DiovanCardiovascular Diabetology 2007, 6:26 http://www.cardiab.com/content/6/1/26
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Results
Characteristics of study sample
Of the study population of 2635 patients with hyperten-
sion who had been treated with ARB monotherapy, a total
of 1083 patients without diabetes were subjected to statis-
tical analysis. Blood examination data are shown in Table
2. Approximately 60% of patients were female and 40%
were male, for both casual blood glucose and HbA1c
measurements. Approximately 65% of patients were aged
over 60 years. The numbers of blood examinations were
2465 and 457 for blood glucose and HbA1c, with 5.08
and 2.95 measurements per subject, respectively.
Relationship of covariates to blood glucose and HbA1c
Table 3 presents the results from linear mixed effect mod-
els fitted to casual blood glucose and HbA1c data. There
was no association between HbA1c level and any of the
covariates of sex, age, medication and "duration of treat-
ment". In contrast to HbA1c, the duration of treatment
was associated with blood glucose level. However, sex,
age, and medication were not associated with blood glu-
cose level. Our study showed no significant differences in
blood glucose and HbA1c levels among the different ARB
agents during the time course of ARB therapy. Dunnett's
multiple-comparison test showed that blood glucose level
was significantly decreased in the periods of "0~3
months" and "3~6 months" compared with "baseline",
but was not significantly different between "6~12
months" and "baseline". The interaction of duration of
treatment and other covariates was not significant (data
not shown). This indicates that the effect of treatment
duration does not depend on the level of other covariates.
Therefore, the tests for individual effects are valid, show-
ing a significant effect of "treatment duration", but no sig-
nificant effect of sex, age, and medication. These results
indicate that the duration of ARB therapy has an influence
on blood glucose level, suggesting a blood glucose-lower-
ing effect of ARBs, at least within 6 months of the start of
treatment.
Discussion
Various opinions exist regarding whether reduction of
insulin sensitivity can induce hypertension. Regarding the
responsible mechanism, the compensatory high plasma
insulin accompanying a reduction of insulin sensitivity is
said to: 1) increase sympathetic nerve activity [9], 2) pro-
mote renal sodium reabsorption [10], 3) induce the
growth of vascular smooth muscle [11], and have other
similar effects that induce or aggravate hypertension. On
the other hand, hypertension itself may cause sym-
pathicotonia and trigger hyperinsulinemia. Furthermore,
Table 2: Frequency distribution of blood examination data
Items
Variables Glucose HbA1c
PATIENT INFORMATION
Number of subjects 485 155
Sex
Female 187 (38.6) 54 (34.8)
Male 298 (61.4) 101 (65.2)
Age, years
20–49 67 (13.8) 20 (12.9)
50–59 103 (21.2) 33 (21.3)
60–69 150 (31.0) 47 (30.3)
70< 165 (34.0) 55 (35.5)
Medication
candesartan cilexetil 177 (36.5) 51 (32.9)
losartan potassium 78 (16.1) 35 (22.6)
olmesartan medoxomil 56 (11.5) 21 (13.5)
telmisartan 56 (11.5) 18 (11.6)
valsartan 118 (24.3) 30 (19.4)
DATA INFORMATION
Number of examinations 2464 457
Treatment duration
0 = "Baseline" 733 (29.8) 150 (32.8)
1 = "~3 M" 1068 (43.3) 132 (28.9)
2 = "3~6 M" 377 (15.3) 89 (19.5)
3 = "6~12 M" 286 (11.6) 86 (18.8)
Abbreviations: HbA1c, hemoglobin A1c. All data are count 
(percentage).
Flow of study population Figure 1
Flow of study population. Medical record reviews for lon-
gitudinal survey data were conducted for 14 months; 2 
months before and 12 months during ARB treatment. 
Detailed criteria for exclusion are described in the Methods.
Study 
population 
Longitudinal 
survey data for 
14 months 
Subjects with hypertension treated with 
ARB monotherapy in Dec 2004 - Nov 2005, 
aged ≥ 20 years, N = 2635 
Subjects without DM
N = 1083 
Complicated 
with DM* 
Blood glucose data
2465 examinations
 N = 485 
HbA1c data 
457 examinations
N = 155 
Removed
YES 
NO Cardiovascular Diabetology 2007, 6:26 http://www.cardiab.com/content/6/1/26
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each may aggravate the other, producing a vicious cycle of
hypertension and high blood glucose.
In the present study, a significant reduction in casual
blood glucose level was observed with ARB administra-
tion. Regarding the mechanism, the general understand-
ing is that after insulin binds to the insulin receptor,
tyrosine phosphorylation inside the cell causes activation
of insulin receptor substrate-1 (IRS-1) and phosphatidyli-
nositol 3-kinase (PI3-kinase) [12]. As a result, the rate of
glucose uptake into the cell increases. Although insulin
resistance itself is still poorly understood, there is evi-
dence that the levels of expression of IRS-3 and PI-3 kinase
are reduced, although there may be many other genetic
abnormalities involved. Folli et al. showed that, in vascu-
lar smooth muscle cells, angiotensin II reduces tyrosine
phosphorylation of IRS-1 by approximately 50% and
reduces binding of IRS-1 to PI3-kinase by 30–50% [13].
ARB and ACE inhibitors block the inhibitory effect of
angiotensin II on insulin signal transmission [3,4]. As a
result, insulin resistance is improved, and there appears to
be a beneficial effect on glucose metabolism. ARBs and
ACE inhibitors are thought to have the same actions. In
the present study, experiments were conducted using ACE
inhibitors as well, but the same trends as for ARBs were
noted, and no statistically significant difference was
observed. The differences between the two could possibly
be due to differences in sample size. In addition, ARBs
block the effects of angiotensin II at the receptor level,
more so than ACE inhibitors. ARBs may thus be more
selective in their effects on the renin-angiotensin system.
The effects of ARBs on glucose metabolism have been
reported in several experiments on animals and cell lines.
Schupp et al. reported that ARBs induce activation of
PPAR γ in cultured adipose cell lines of mice, which par-
tially removes insulin resistance [14]. In addition, Fujim-
oto et al. showed with the same cell line that telmisartan
administration increased the uptake of glucose and
expression of GLUT4 protein [15]. Furthermore, Furu-
hashi et al. showed that blocking of the renin-angiotensin
system by an ARB increased the plasma adiponectin level
[16]. This is hypothesized to be the mechanism by which
ARBs reduce blood glucose. However, even in the case of
animal experiments, few reports are available concerning
how long ARBs affect glucose metabolism. Among clinical
trials as well, there are only a few trials, over short time
periods and with small numbers of cases.
A particular feature of this study is that it involved a retro-
spective survey, which included examination of the
changes in blood glucose level over time in 485 hyperten-
sive patients with no glucose metabolism abnormalities,
spanning 12 months of ARB therapy. In the present study,
we observed no statistically significant difference in
results among the different ARBs. In addition, our study
showed no significant difference in HbA1c level during
the time course of ARB therapy. However, patients with
Table 3: Relationship of covariates to blood glucose and HbA1c measurements
Glucose (mg/dl) HbA1c (%)
Variables LS mean ± SE (95% CI) P value LS mean ± SE (95% CI) P value
Sex 0.2268 0.8062
Female 107.80 ± 1.34 (105.15, 110.44) 5.51 ± 0.10 (5.31, 5.71)
Male 109.70 ± 1.07 (107.58, 111.81) 5.48 ± 0.07 (5.33, 5.64)
Age, years 0.075 0.3041
20–49 105.09 ± 2.10 (100.96, 109.22) 5.33 ± 0.15 (5.01, 5.64)
50–59 108.83 ± 1.75 (105.38, 112.27) 5.44 ± 0.13 (5.17, 5.71)
60–69 109.69 ± 1.43 (106.88, 112.51) 5.62 ± 0.10 (5.42, 5.83)
70< 111.37 ± 1.32 (108.77, 113.97) 5.61 ± 0.09 (5.42, 5.79)
Medication 0.4579 0.6887
candesartan cilexetil 110.93 ± 1.31 (108.34, 113.51) 5.62 ± 0.10 (5.41, 5.82)
losartan potassium 107.73 ± 2.01 (103.77, 111.69) 5.52 ± 0.12 (5.28, 5.77)
olmesartan medoxomil 106.99 ± 2.24 (102.58, 111.40) 5.37 ± 0.15 (5.06, 5.68)
telmisartan 108.57 ± 2.16 (104.31, 112.83) 5.43 ± 0.16 (5.10, 5.76)
valsartan 109.51 ± 1.56 (106.44, 112.59) 5.55 ± 0.12 (5.30, 5.81)
Treatment duration <.0001 0.6014
0 = "Baseline" 111.98 ± 1.16 (109.70, 114.27) reference* 5.51 ± 0.07 (5.37, 5.66) reference*
1 = "~3 M" 105.86 ± 1.13 (103.64, 108.09) <.0001* 5.50 ± 0.07 (5.35, 5.65) 0.8209*
2 = "3~6 M" 107.78 ± 1.48 (104.87, 110.69) 0.0081* 5.44 ± 0.08 (5.28, 5.61) 0.2582*
3 = "6~12 M" 109.36 ± 1.63 (106.16, 112.56) 0.1308* 5.54 ± 0.08 (5.37, 5.70) 0.7457*
Abbreviations: HbA1c, hemoglobin A1c; LS means, least squares means; SE, standard error; CI, confidence interval.
*Dunnett-Hsu post-hoc analysis.Cardiovascular Diabetology 2007, 6:26 http://www.cardiab.com/content/6/1/26
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diabetes were excluded in the present study, and this may
have been the reason for the lack of significant difference
in HbA1c level.
Within the first 3 months of ARB therapy, a significant
decrease in blood glucose level was noted. This decrease
was maintained for 6 months, though blood glucose level
subsequently returned to the same level as at the start of
administration, and at 12 months, no significant differ-
ence from the baseline level was noted. Since blood pres-
sure was controlled from the start of administration, the
initial reduction in blood glucose level appears to have
been an effect of ARBs and/or the reduction of blood pres-
sure. However, our observation that blood glucose level
tended to increase again after 6 months, together with pre-
vious reports that thiazide diuretics and β-blockers reduce
insulin sensitivity [17-19], suggest that the initial reduc-
tion in blood glucose appears to have been an effect of
ARB treatment.
Limitations
Further study on whether the blood glucose-lowering
effect by suppression of the renin-angiotensin system was
direct or through some other factor is needed. Although
there have been reports that calcium channel blockers and
α-blockers improve insulin resistance and glucose metab-
olism abnormalities, this was not examined in the present
study. We are looking into these issues as future subjects
of research.
Conclusion
The duration of ARB therapy was significantly associated
with casual glucose level in nondiabetic adults with
hypertension regardless of treatment with candesartan
cilexetil, losartan potassium, olmesartan medoxomil, tel-
misartan, or valsartan. Our findings not only support the
notion that ARBs can improve glucose metabolism via
blocking the inhibitory effect of angiotensin II on insulin
signal transmission as suggested elsewhere, but also dem-
onstrate that the effects of ARBs on glucose metabolism
are associated with the course of treatment, suggesting a
blood glucose-lowering effect within 6 months of the start
of ARB therapy.
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